VEGFA and glioblastoma: Interestingly, the combination of anti-VEGF + anti-PD-L1 (without IM) did not improve the overall survival of GBM-bearing mice (Figure 7O), consistent with the failed clinical trials combining PD-1/PD-L1 checkpoint inhibitors with antiangiogenic agents (NCT02337491, NCT03291314), highlighting the importance of imipramine for the observed efficacy of this novel triple therapy (Figure 7O).